$14.59 -0.6 -3.8%
Last Trade - 7:28pm
| Market Cap | £277.3m |
| Enterprise Value | £251.2m |
| Revenue | £n/a |
| Position in Universe | 3747th / 6713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 9.38 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | July 3, 2013 |
| Public Since | June 15, 2018 |
| No. of Shareholders: | 37 |
| No. of Employees: | 17 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 25,865,542 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 10 N High St Ste 200, WEST CHESTER, 19380-3014, United States |
| Web | http://www.verrica.com/ |
| Phone | +1 484 4533300 |
| Contact | () |
| Auditors | KPMG LLP |
As of 7:28pm, shares in Verrica Pharmaceuticals Inc are trading at $14.59, giving the company a market capitalisation of £277.3m. This share price information is delayed by 15 minutes.
Shares in Verrica Pharmaceuticals Inc are currently trading at $14.59 and the price has moved by 17.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verrica Pharmaceuticals Inc price has moved by -5.28% over the past year.
Of the analysts with advisory recommendations for Verrica Pharmaceuticals Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Verrica Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Verrica Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Verrica Pharmaceuticals Inc does not currently pay a dividend.
Verrica Pharmaceuticals Inc does not currently pay a dividend.
Verrica Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Verrica Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Verrica Pharmaceuticals Inc are currently trading at $14.59, giving the company a market capitalisation of £277.3m.
Here are the trading details for Verrica Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Verrica Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Verrica Pharmaceuticals Inc are currently priced at $14.59. At that level they are trading at 31.93% discount to the analyst consensus target price of 0.00.
Analysts covering Verrica Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.518 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verrica Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 54.13%. At the current price of $14.59, shares in Verrica Pharmaceuticals Inc are trading at 50.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Verrica Pharmaceuticals Inc based on the size of their shareholding:
